Stevens-Johnson syndrome induced by paclitaxel in a patient with squamous cell carcinoma of the lung: a case report.
We treated a 53-year-old man with advanced squamous cell carcinoma of the lung who had developed Stevens-Johnson syndrome, a life-threatening cutaneous reaction, after systemic chemotherapy consisting of carboplatin and paclitaxel. A critical assessment disclosed circumstantial evidence pointing to paclitaxel as the likely cause of this complication. As far as we are aware, this account is the first description of a paclitaxel-induced Stevens-Johnson syndrome. This case serves as an alert for the need to observe patients closely for potentially dangerous cutaneous reactions to paclitaxel therapy.
Hiraki
Akio
A
Department of Respiratory Medicine, National Sanyo Hospital, Respiratory Disease Center, Ube, Yamaguchi, Japan.
Aoe
Keisuke
K
Murakami
Tomoyuki
T
Maeda
Tadashi
T
Eda
Ryosuke
R
Takeyama
Hiroyasu
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000473:pathology
D016190:Carboplatin; D017239:Paclitaxel